tiprankstipranks
Dexcom (DE:DC4)
XETRA:DC4

Dexcom (DC4) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

DC4 Analyst Ratings

Strong Buy
16Ratings
15 Buy
1 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Dexcom
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DC4 Stock 12 Month Forecast

Average Price Target

€144.65
▲(21.37% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Dexcom in the last 3 months. The average price target is €144.65 with a high forecast of €158.33 and a low forecast of €128.53. The average price target represents a 21.37% change from the last price of €119.18.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"76":"€76","159":"€159","96.75":"€96.8","117.5":"€117.5","138.25":"€138.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":158.32865,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€158.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":144.64719195,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€144.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":128.52561,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€128.53</span>\n  </div></div>","useHTML":true}}],"tickPositions":[76,96.75,117.5,138.25,159],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,119.18,122.19143461538462,125.20286923076924,128.21430384615385,131.22573846153847,134.23717307692309,137.2486076923077,140.26004230769232,143.27147692307693,146.28291153846155,149.29434615384616,152.30578076923078,155.3172153846154,{"y":158.32865,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,119.18,121.13901476538462,123.09802953076924,125.05704429615385,127.01605906153847,128.97507382692308,130.9340885923077,132.89310335769233,134.85211812307693,136.81113288846154,138.77014765384615,140.7291624192308,142.6881771846154,{"y":144.64719195,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,119.18,119.89889307692309,120.61778615384615,121.33667923076924,122.05557230769232,122.77446538461538,123.49335846153846,124.21225153846154,124.93114461538462,125.65003769230769,126.36893076923077,127.08782384615385,127.80671692307692,{"y":128.52561,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":109.24,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.3,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.16,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.1,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.4,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.5,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.09,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.38,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.48,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.88,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.2,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.18,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€158.33Average Price Target€144.65Lowest Price Target€128.53
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity
€135.05
Buy
13.31%
Upside
Reiterated
04/25/24
DexCom price target raised to $145 from $144 at CanaccordDexCom price target raised to $145 from $144 at Canaccord
BTIG
€145.29
Buy
21.91%
Upside
Reiterated
04/15/24
DexCom price target raised to $156 from $150 at BTIGDexCom price target raised to $156 from $150 at BTIG
UBS
€151.81
Buy
27.38%
Upside
Reiterated
04/10/24
DexCom (DXCM) PT Raised to $163 at UBSUBS analyst Danielle Antalffy raised the price target on DexCom (NASDAQ: DXCM) to $163.00 (from $153.00) while maintaining a Buy rating.
Oppenheimer
€135.05
Buy
13.31%
Upside
Reiterated
03/06/24
Oppenheimer reiterates Outperform Rating on DexCom (DXCM)Oppenheimer analyst Steven Lichtman reiterated an Outperform rating and $145.00 price target on DexCom (NASDAQ: DXCM) after non-insulin CGM was approved.
Bank of America Securities
€158.33
Buy
32.85%
Upside
Reiterated
03/05/24
Analysts Conflicted on These Healthcare Names: AMN Healthcare Services (NYSE: AMN) and Dexcom (NASDAQ: DXCM)

Best Analysts Covering Dexcom

Which Analyst Should I Follow If I Want to Buy DE:DC4 and Sell After:
1 Month
Steven LichtmanOppenheimer
Success Rate
25/42 ratings generated profit
60%
Average Return
+3.40%
reiterated a buy rating 2 months ago
Copying Steven Lichtman's trades and holding each position for 1 Month would result in 59.52% of your transactions generating a profit, with an average return of +3.40% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Mathew BlackmanStifel Nicolaus
Success Rate
16/20 ratings generated profit
80%
Average Return
+14.04%
reiterated a buy rating 9 days ago
Copying Mathew Blackman's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +14.04% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Mathew BlackmanStifel Nicolaus
Success Rate
17/20 ratings generated profit
85%
Average Return
+37.52%
reiterated a buy rating 9 days ago
Copying Mathew Blackman's trades and holding each position for 1 Year would result in 85.00% of your transactions generating a profit, with an average return of +37.52% per trade.
2 Years
Mathew BlackmanStifel Nicolaus
Success Rate
18/20 ratings generated profit
90%
Average Return
+58.03%
reiterated a buy rating 9 days ago
Copying Mathew Blackman's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +58.03% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DC4 Analyst Recommendation Trends

Rating
Dec 23
Jan 24
Feb 24
Mar 24
Apr 24
Strong Buy
7
0
0
0
0
Buy
18
17
21
27
32
Hold
2
1
3
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
18
24
29
35
In the current month, DC4 has received 32 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. DC4 average Analyst price target in the past 3 months is €144.65.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

DC4 Financial Forecast

DC4 Earnings Forecast

Next quarter’s earnings estimate for DC4 is €0.36 with a range of €0.33 to €0.42. The previous quarter’s EPS was €0.30. DC4 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 63.27% of the time in the same period. In the last calendar year DC4 has Outperformed its overall industry.
Next quarter’s earnings estimate for DC4 is €0.36 with a range of €0.33 to €0.42. The previous quarter’s EPS was €0.30. DC4 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 63.27% of the time in the same period. In the last calendar year DC4 has Outperformed its overall industry.

DC4 Sales Forecast

Next quarter’s sales forecast for DC4 is €967.50M with a range of €959.20M to €978.99M. The previous quarter’s sales results were €859.53M. DC4 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 59.02% of the time in the same period. In the last calendar year DC4 has Outperformed its overall industry.
Next quarter’s sales forecast for DC4 is €967.50M with a range of €959.20M to €978.99M. The previous quarter’s sales results were €859.53M. DC4 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 59.02% of the time in the same period. In the last calendar year DC4 has Outperformed its overall industry.

DC4 Stock Forecast FAQ

What is DE:DC4’s average 12-month price target, according to analysts?
Based on analyst ratings, Dexcom’s 12-month average price target is €144.65.
    What is DE:DC4’s upside potential, based on the analysts’ average price target?
    Dexcom has 21.37% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Dexcom a Buy, Sell or Hold?
          Dexcom has a conensus rating of Strong Buy, which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Dexcom’s share price target?
            The average share price target for Dexcom is €144.65. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €158.33 ,and the lowest forecast is €128.53. The average share price target represents 21.37% Increase from the current price of €119.18.
              What do analysts say about Dexcom?
              Dexcom’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of Dexcom?
                To buy shares of DE:DC4, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis